Inactive Instrument

OHR Pharmaceutical Inc Stock Nasdaq

US67778H3093

Biotechnology & Medical Research

Valuation: OHR Pharmaceutical Inc

Market Cap	1.28M 1.12M 1.06M 965K 1.81M 122M 1.82M 12.67M 4.91M 62.57M 4.8M 4.69M 201M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.12M 1.06M 965K 1.81M 122M 1.82M 12.67M 4.91M 62.57M 4.8M 4.69M 201M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news: OHR Pharmaceutical Inc

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
24-06-27	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
24-05-28	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: OHR Pharmaceutical Inc

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	2021-10-31

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	2025-01-03

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OHR PHARMACEUTICAL INC	+1.98%	+18.80%	-	-	1.39M
LONZA GROUP AG	-0.14%	+4.33%	+9.88%	+31.73%	48.01B
IQVIA HOLDINGS INC.	-1.67%	+1.66%	+53.29%	+33.82%	45.27B
BEONE MEDICINES AG	+0.40%	+3.44%	+10.41%	+90.63%	40.93B
REVOLUTION MEDICINES, INC.	+2.64%	+8.10%	+385.59%	+599.75%	42.84B
CELLTRION, INC.	-0.62%	-1.61%	+5.30%	+46.02%	29.6B
MEDPACE HOLDINGS, INC.	-0.71%	+0.50%	+26.12%	+151.49%	17.32B
EUROFINS SCIENTIFIC SE	-0.46%	+0.62%	+24.98%	+41.01%	15.34B
ASCENDIS PHARMA A/S	-2.15%	-4.75%	-	-	15.15B
TEMPUS AI, INC.	+3.09%	+9.16%	+9.88%	-	14.84B
Average	+0.32%	+1.02%	+65.68%	+142.06%	29.92B
Weighted average by Cap.	+0.24%	+1.56%	+82.51%	+154.91%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company